Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gibb

Showing results (331-340 of 368) with videos related to

Pageof 37
Sort By:
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
American Journal of Hematology|February 11, 2022
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in AfricaPeter Olupot-Olupot, Roisin Connon, Sarah Kiguli, et al.
The New England Journal of Medicine|June 13, 2025
Intravenous Rehydration for Severe Acute Malnutrition with GastroenteritisKathryn Maitland, San Maurice Ouattara, Hadiza Sainna, et al.
The Lancet. Child & Adolescent Health|March 13, 2026
Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trialKathryn Maitland, Hadiza Sainna, Roisin Connon, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Plos Medicine|December 5, 2018
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trialCissy Kityo, Alexander J Szubert, Abraham Siika, et al.
HIV Medicine|November 3, 2009
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection, Steve Welch, Mike Sharland, et al.
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
Pageof 37

Showing results (331-340 of 368) with videos related to

Sort By:
Pageof 37
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
American Journal of Hematology|February 11, 2022
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in AfricaPeter Olupot-Olupot, Roisin Connon, Sarah Kiguli, et al.
The New England Journal of Medicine|June 13, 2025
Intravenous Rehydration for Severe Acute Malnutrition with GastroenteritisKathryn Maitland, San Maurice Ouattara, Hadiza Sainna, et al.
The Lancet. Child & Adolescent Health|March 13, 2026
Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trialKathryn Maitland, Hadiza Sainna, Roisin Connon, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Plos Medicine|December 5, 2018
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trialCissy Kityo, Alexander J Szubert, Abraham Siika, et al.
HIV Medicine|November 3, 2009
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection, Steve Welch, Mike Sharland, et al.
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
Pageof 37